Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics has announced the successful completion of the first dosing of its novel IV-infused psilocin formulation, TRP-8803, marking a global first in psychedelic treatment. The study, focused on establishing safety and optimizing dosage for future Phase 2a trials, has shown promising results with the potential to revolutionize the administration of psychedelic therapy. The company anticipates further results in Q3 2024, which could significantly impact its clinical trial pipeline for multiple medical conditions.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.
